Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Cook brings extensive pharmaceutical legal experience, having previously served as Senior Vice President and General Counsel at Sage Therapeutics, with prior legal leadership positions at Aegerion, ViaCell, and Biogen. Her expertise spans corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy. CEO Steven Basta emphasized Cook's potential impact on building Phathom into a leading GI company. Cook expressed enthusiasm about joining Phathom during its commercial evolution phase, highlighting the company's potential to transform acid-related GI disease treatment standards.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced that the FDA has corrected the Orange Book listing for VOQUEZNA® (vonoprazan) tablets, confirming its 10-year New Chemical Entity (NCE) exclusivity period through May 3, 2032. VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB), is approved for treating heartburn associated with Non-Erosive GERD and Erosive GERD in adults. The product is also available as VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection treatment. This correction reinforces the long-term commercial potential for this novel GI treatment, ensuring market protection for the full statutory period.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced that the FDA has approved their Citizen Petition and will extend regulatory exclusivity for VOQUEZNA (vonoprazan) tablets through May 3, 2032. This grants the company 10 years of New Chemical Entity exclusivity for their first-in-class potassium-competitive acid blocker (PCAB). VOQUEZNA is currently marketed in the US for treating heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and as VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection treatment. This FDA decision strengthens Phathom's market position by protecting their intellectual property rights for an extended period.

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, has announced its participation in three upcoming investor conferences:

1. H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 4:00 p.m. ET in New York

2. Jefferies Global Healthcare Conference on June 5, 2025, at 9:55 a.m. ET in New York

3. Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET in Miami Beach

The company will conduct one-on-one meetings at all events. Live webcasts and 90-day archived recordings will be available on Phathom's investor relations website.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, along with associated inducement awards. The Board granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the remainder vesting in 36 monthly installments. Additionally, Bentley received 57,143 restricted stock units vesting in three equal annual installments and 50,000 restricted stock units vesting in two equal annual installments.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and DUAL PAK® for H. pylori infection treatment.

Phathom Pharmaceuticals reported Q1 2025 financial results and strategic changes. VOQUEZNA achieved over 390,000 prescriptions to date, with Q1 net revenues of $28.5 million. The company implemented cost reductions and leadership changes, including a 6% workforce reduction, aiming to cut 2025 operating expenses by $60-70M. New appointments include Jonathan Bentley as SVP of Sales and Ted Schroeder to the Board. Q1 saw 127,000 VOQUEZNA prescriptions filled, an 8% growth despite seasonal challenges. The company maintains strong commercial coverage for over 120M lives. Financial results show increased net loss of $94.3M compared to $82.9M in Q1 2024. Cash position stands at $212.3M, which management believes sufficient to achieve operational profitability by 2026.

Phathom Pharmaceuticals (Nasdaq: PHAT) will present real-world data for VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) in San Diego from May 3-6, 2025. The presentation includes two posters analyzing real-world treatment patterns and patient characteristics of VOQUEZNA-treated GERD patients.

VOQUEZNA is the first FDA-approved treatment of its kind for adults with Non-Erosive GERD and all severities of Erosive Esophagitis. The company will host a Product Theater and maintain booth #1743 at the conference.

Key events include:

• VOQUEZNA Product Theater on May 4, 2025 (12:15 PM PT)
• Independent Medscape CME Symposia on May 4 (6:00 PM PT)
• Real-world data poster presentations on May 5 (12:30 PM PT)

Phathom Pharmaceuticals (NASDAQ: PHAT) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, at 8:00 am EDT. The company will host a live webcast accessible through their investor relations website, with a recording available for 90 days afterward.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan) tablets in the United States. Their product lineup includes treatments for:

• Non-Erosive GERD heartburn relief in adults
• Healing and maintenance of Erosive GERD in adults
• H. pylori infection treatment through VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®

Phathom Pharmaceuticals (PHAT) has appointed Ted Schroeder to its Board of Directors. Schroeder brings over 30 years of experience leading biopharmaceutical companies, with expertise in building commercial organizations, launching new therapies, and guiding companies through strategic milestones.

Board Chairman Michael Cola highlighted Schroeder's appointment comes at a pivotal period for Phathom, particularly as the company focuses on unlocking the full potential of VOQUEZNA®. Schroeder's operational and commercial expertise is expected to support Phathom's commercial momentum in delivering first-in-class therapies for gastrointestinal diseases.